Patents Represented by Attorney, Agent or Law Firm Robert P. Blackburn
  • Patent number: 6592844
    Abstract: A process is described for preparing microspheres, films and coatings from protein or modified protein in which the protein product is stabilized by carrying out the preparation in the presence of an aqueous solution of at least one &agr;-hydroxy acid. The microspheres, films and coatings so produced have improved stability in aqueous solution.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: July 15, 2003
    Assignees: Chiron Corporation, University of Nottingham
    Inventors: Allan G. A. Coombes, Wu Lin, Derek T. O'Hagen, Stanley S. Davis
  • Patent number: 6589745
    Abstract: A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: July 8, 2003
    Assignee: Chiron Corporation
    Inventor: Joerg Kaufmann
  • Patent number: 6586244
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
  • Patent number: 6586222
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • Patent number: 6579521
    Abstract: Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 17, 2003
    Assignee: Chiron Corporation
    Inventor: David Sahner
  • Patent number: 6572881
    Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: June 3, 2003
    Assignee: Chiron Corporation
    Inventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
  • Patent number: 6573238
    Abstract: Methods for preparing biodegradable microparticles are provided. Also provided are microparticles prepared by the method which include IGF-1 entrapped therein. The microparticles allow for controlled release of IGF-1 and other polypeptides over prolonged periods of time.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: June 3, 2003
    Assignee: Chiron Corporation
    Inventors: Bret Shirley, Maninder Hora, Derek O'Hagan, Manmohan Singh
  • Patent number: 6569450
    Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: May 27, 2003
    Assignee: Chiron Corporation
    Inventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
  • Patent number: 6569679
    Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 27, 2003
    Assignee: Chiron Corporation
    Inventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
  • Patent number: 6566063
    Abstract: The invention features methods for detection of metastatic and potentially metastatic cancerous cells by detection of expression of a gland-specific Ets transcription factor (GSEF) sequence, which encodes an Ets-domain containing protein. The invention also features methods and compositions for modulation of the polypeptide and/or gene activity for prophylactic and therapeutic purposes, such as inhibition of progression of a cell to a metastatic cancerous cell.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: May 20, 2003
    Assignee: Chiron Corporation
    Inventors: Joerg Kaufmann, Hong Xin, Greg Harrowe
  • Patent number: 6562346
    Abstract: The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: May 13, 2003
    Assignee: Chiron Corporation
    Inventors: Xavier Paliard, Michael Houghton, Mark Selby
  • Patent number: 6548634
    Abstract: Peptidic compositions having FGF receptor affinity, as well as fusion proteins and oligomers of the same, are provided. The subject peptidic compounds are characterized by having little or no homology to naturally occurring bFGF. The subject fusion proteins include the peptidic composition linked to an oligomerization domain, either directly or through a linking group and optionally further include a heparin binding domain. The subject peptidic compositions, fusion proteins and oligomers thereof find use in a variety of applications, including both research and therapeutic applications, in which FGF receptor ligands are employed.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: April 15, 2003
    Assignee: Chiron Corporation
    Inventors: Marcus Ballinger, Michael Kavanaugh
  • Patent number: 6544523
    Abstract: The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells and in vitro or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: April 8, 2003
    Assignee: Chiron Corporation
    Inventor: Keting Chu
  • Patent number: 6544962
    Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: April 8, 2003
    Assignee: Matrix Pharmaceutical, Inc.
    Inventors: Richard E. Jones, Ning Y. Yu
  • Patent number: 6537745
    Abstract: The present invention is directed to an antigen diluent or buffer for antigens, in particular HCV recombinant antigens, comprising a reducing agent. The antigen diluent or buffer serves as a stabilizing buffer for the antigens. The present invention is also directed to antigen diluents or buffers for use in an automated immunoassay.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: March 25, 2003
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, Phillip Arcangel, Stephen Tirell, Wanda Zeigler
  • Patent number: 6534064
    Abstract: A method for producing a cellular immune response in a vertebrate subject comprising administering to the vertebrate subject a vaccine composition comprising a protein particle antigen and a pharmaceutically acceptable excipient is disclosed.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: March 18, 2003
    Assignee: Chiron Corporation
    Inventors: Derek O'Hagan, Manmohan Singh
  • Patent number: 6531276
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: March 11, 2003
    Assignee: Chiron Corporation
    Inventors: Paul A. Luciw, Dino Dina
  • Patent number: 6531307
    Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (eg. HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: March 11, 2003
    Assignee: Chiron Corporation
    Inventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
  • Patent number: 6525102
    Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: February 25, 2003
    Assignee: Chiron Corporation
    Inventors: Bao-Lu Chen, Maninder S. Hora
  • Patent number: 6521423
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: February 18, 2003
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer